A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies.
| Image |  |
|---|---|
| Description | scientific article |
| Author/s |
author: David D. Hurd Timothy S Pardee Leslie R Ellis Lance Miller |
| Publication date | August 27, 2014 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |